Loading...
Loading...
NYSE: NVO
Healthcare · Drug Manufacturers - General
Market Cap
$166.43B
52w High
$81.44
52w Low
$35.85
P/E
10.25
Volume
25.38M
Outstanding Shares
4.44B
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Company profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Valuation
Stock splits
Profitability & growth
Analyst consensus
23
Buy
13
Hold
3
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
View
EPS
Actual vs estimate by quarter
$0.97
$0.93
$1.02
$0.77
$1.00
$0.92
—
Revenue
Actual vs estimate by quarter
$12.13B
$12.3B
$11.78B
$12.37B
$12.31B
$11.91B
—